Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Ends Regularly Scheduled Patient-Focused Drug Development Meetings

Sep 29 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

“Patient Voice” Report Puts Chronic Fatigue Symptoms, Treatments In Benefit/Risk Framework

Oct 07 2013

Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy

Jul 07 2014

Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta

Sep 23 2016

20 Is The Loneliest Number: FDA Disease Meeting Schedule Leaves Some Worried About Exclusion

Oct 24 2012

Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers

Jun 10 2015

FDA Quietly Consults Patients To Understand <em>Vimizim's</em> Six-Minute Walk Significance

Dec 01 2014

FDA’s Patient-Focused Drug Development Meetings Inspire Imitators

May 19 2014

FDA's 21<sup>st</sup> Century Cures Plan Gives Patient-Focused Drug Development A Boost

Jul 10 2017

Hereditary Angioedema Patients Urge Work On Dosing, Product Shortages

Sep 28 2017

US FDA's Centralized Patient Affairs Office Aims For No Disruption

Sep 14 2017

You Just Have To Wait: FDA Can't Hurry PDUFA VI Guidances

Aug 15 2016

Additional Topics

United States Drug Approval Standards FDA Regulation BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.